登录
Consensus of Chinese Experts on Neoadjuvant and Conversion Therapies for Hepatocellular Carcinoma: 2023 Update [0.03%] 中国肝细胞癌新辅助和转化治疗专家共识（2023版）
Xinyu Bi,Haitao Zhao,Hong Zhao et al. Xinyu Bi et al.
Hepatocellular carcinoma (HCC) is a common malignancy in China, with high recurrence rate and low resection rate among patients first diagnosed. Preoperative treatments including neoadjuvant and conversion therapy have the potential to over...
Incorporating ALBI Grade with Geriatric Nutritional Risk Index Enhances Hepatocellular Carcinoma Risk Stratification [0.03%] 结合ALBI分级和老年营养风险指数可改善肝细胞癌的风险分层
Heechul Nam,Pil Soo Sung,Sung Won Lee et al. Heechul Nam et al.
Introduction: Despite its prognostic impact, nutritional status has not yet been integrated into the assessment of hepatocellular carcinoma (HCC). This study investigated the association between geriatric nutritional risk...
Real-World Study of Systemic Treatment after First-Line Atezolizumab plus Bevacizumab for Hepatocellular Carcinoma in Asia-Pacific Countries [0.03%] 亚太地区接受了一线阿特珠单抗联合贝伐珠单抗治疗后系统性治疗的肝细胞癌患者的现实世界研究
Choong-Kun Lee,Changhoon Yoo,Jung Yong Hong et al. Choong-Kun Lee et al.
Introduction: Atezolizumab plus bevacizumab is a commonly used first-line regimen for advanced hepatocellular carcinoma (HCC) treatment owing to its superior outcomes compared to sorafenib. However, optimal subsequent tre...
The Impact of Radiation Dose and Tumour Burden on Outcomes in Hepatocellular Carcinoma: 11-Year Experience in a 413-Patient Cohort Treated with Yttrium-90 Resin Microsphere Radioembolisation [0.03%] 放射剂量和肿瘤负荷对肝细胞癌的影响：一项关于钇-90树脂微球放射栓塞治疗的413名患者11年的经验研究
Kaina Chen,Aaron K T Tong,Fiona N N Moe et al. Kaina Chen et al.
Introduction: Transarterial radioembolisation (RE) using yttrium-90 (Y-90) microspheres is a widely used locoregional therapy for a broad spectrum of hepatocellular carcinoma (HCC) given its favourable safety profile. We ...
Higher Risk of Proteinuria with Atezolizumab plus Bevacizumab than Lenvatinib in First-Line Systemic Treatment for Hepatocellular Carcinoma [0.03%] 与仑伐替尼相比，阿特朱单抗联合贝伐珠单抗治疗肝细胞癌一线系统性治疗的蛋白尿风险更高
Jiwon Yang,Won-Mook Choi,Hyung-Don Kim et al. Jiwon Yang et al.
Introduction: Proteinuria presents a challenging complication during systemic therapy for hepatocellular carcinoma (HCC). This study aims to identify risk factors for proteinuria in patients with HCC treated with atezoliz...
Particle Therapy for Intrahepatic Cholangiocarcinoma: A Multicenter Prospective Registry Study, Systematic Review and Meta-Analysis [0.03%] 颗粒治疗肝内胆管癌的多中心前瞻性注册研究、系统回顾和荟萃分析
Masashi Mizumoto,Kei Shibuya,Kazuki Terashima et al. Masashi Mizumoto et al.
Introduction: A prospective study was started in May 2016 to evaluate the efficacy and safety of particle therapy for intrahepatic cholangial carcinoma (ICC). To compare treatment modalities, we also conducted a meta-anal...
Depth of Radiographic Response as an Independent Prognostic Factor for Patients with Initially Unresectable Hepatocellular Carcinoma Receiving Hepatectomy following Targeted Therapy plus Immunotherapy [0.03%] 靶向治疗联合免疫治疗后肝切除术患者的放射学缓解深度是初始不可切除的 hepatocellular carcinoma患者独立于预后的因素
Bin Xu,Lu-Na Wang,Zi-Yi Wang et al. Bin Xu et al.
Introduction: Surgical resection following systemic therapy is feasible in patients with initially unresectable hepatocellular carcinoma (HCC). However, postoperative tumor recurrence is common after surgery, and the fact...
18F-FDG PET/CT Predicts the Prognosis of Patients with Hepatocellular Carcinoma Undergoing Liver Transplantation [0.03%] 18F-FDG正电子发射断层扫描/计算机体层摄影预测肝癌患者肝脏移植后的预后情况
Wen-Jing Zheng,Yang Xu,Hui Tan et al. Wen-Jing Zheng et al.
Introduction: In addition to radical resection, liver transplantation (LTx) is an effective treatment for hepatocellular carcinoma (HCC). However, tumor recurrence limits the efficacy of LTx in some patients. This study i...
Shuichiro Shiina,Ryosuke Tateishi,Joon Il Choi et al. Shuichiro Shiina et al.
Globally, the incidence and associated mortality of primary liver cancer have been steadily increasing. Currently, 80% of cases are found in Asia. Curative resection is applicable in only 20% of patients; therefore, various nonsurgical trea...